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Abstract
Several single nucleotide polymorphism (SNP) genome-wide association studies (GWAS) have 
been completed in multiple sclerosis. Follow-up studies of the variants with the most promising 
rankings, especially when supplemented by informed candidate gene selection, have proven to be 
extremely successful. We report here the results of a multi-stage replication analysis of the 
putatively associated SNPs identified in the Wellcome Trust Case-Control Consortium non-
synonymous SNP screen. In total the replication sample consisted of 3444 patients and 2595 
controls. A combined analysis of the nsSNP screen and replication data provides evidence 
implicating a novel additional locus, rs3748816 in MMEL1 (OR=1.16, p=3.54×10−6) in multiple 
sclerosis susceptibility.
Keywords
Multiple Sclerosis; MMEL1; genetics
Introduction
Multiple sclerosis (MS) is considered to be an autoimmune disease of the central nervous 
system (CNS) that is characterised pathologically by inflammation, demyelination and 
axonal degeneration.1 Epidemiological evidence suggests that it results from unknown 
environmental factors acting on genetically susceptible individuals.2; 3
In the last two years the application of high-throughput genotyping methodologies has 
resulted in rapid progress in the identification of relevant susceptibility genes in MS. To date 
five Single Nucleotide Polymorphism (SNP) Genome-Wide Association Studies (GWAS) 
have been performed in MS; four based on indirectly screening common variation through 
linkage disequilibrium (LD)4–7 and the fifth based on directly typing non-synonymous 
coding SNPs (nsSNPs).8 It is this last study, performed as part of the Wellcome Trust Case 
Control Consortium (WTCCC) that has provided the foundation for the work reported here.
Individually none of the five MS GWAS thus far completed succeeded in identifying 
statistically unequivocal association at the screening stage (outside the expected association 
with the Major Histocompatibility Complex, MHC) although each provides an invaluable 
ranking of the variants tested. The extent to which the higher ranges of such rankings are 
enriched for genuine associations depends upon the power of the study and the prior odds 
that the variants tested are causative, or are in tight LD with such. Follow up studies of the 
variants with the most promising rankings, especially when supplemented by informed 
candidate gene selection, have proven to be extremely successful in MS. For example, by 
extending the typing of a modest number of the most promising variants identified in the 
WTCCC nsSNP screen we have already identified association with the tyrosine kinase 2 
gene (TYK2) and MS.9 Similar highly focused replication efforts based on GWAS results 
have been equally successful in other complex genetic diseases such as celiac disease,10 
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type I diabetes11 and rheumatoid arthritis.12 In this article we report our most recent efforts 
to mine more deeply into the ranking generated in the nsSNP screen.8
Results
A two stage replication effort was employed in this study. In the first stage 1664 of the most 
promising markers identified in the nsSNP screen were typed in an independent set of 1038 
cases and 1379 controls. These new data were combined with the original data from the 
nsSNP screen in order to provide a refined ranking. The results of this extension analysis are 
provided in Supplementary Table S1. In stage 2 of our replication effort we chose the 13 
most promising SNPs identified from the extension analysis for further investigation in 2406 
cases and 1216 controls. Five SNPs were found to have p < 10−4, however as rs601338 and 
rs602662 are in tight LD we only considered rs602662 further (the more strongly 
associated). Of the remaining 331 SNPs with a p < 0.05 we chose a further nine SNPs that 
were within candidate genes. As one of these SNPs (rs12912505) failed manufacture, in 
total we genotyped 12 SNPs.
The results of the 12 SNPs analysed in both replication stages are shown in Table 2 along 
with the combined analysis of all available data from the nsSNP screen, stage 1 and stage 2 
replication efforts. The population specific results for the top 12 SNPs are shown in 
Supplementary Table S2. Using the Breslow-Day test, some evidence for heterogeneity was 
shown for one SNP (rs379707). A random effects model was therefore applied for the 
analysis of this SNP, though it did not alter the Odds Ratio (OR) (data not shown). In the 
combined analysis of all available data, the most significant association was with rs3748816 
which lies in the membrane metalloendopeptidase-like 1 gene (MMEL1) (p=3.54×10−6, 
OR=1.16, 95% CI=1.09–1.24). The modest power in the second stage limits the extent to 
which the evidence for association is increased by this typing. However the result for 
rs3748816 remains nominally significant even if corrected for the number of tests performed 
in the original screen. A detailed plot of the effect size of this variant within MMEL1 by 
country of ascertainment is shown in Figure 1.
Discussion
By systematically extending the analysis of the putatively associated SNPs identified in our 
nsSNP GWAS we provide suggestive evidence implicating an additional locus (rs3748816 
in MMEL1) involved in MS susceptibility. The SNP rs3748816 is located in exon 15 of 
MMEL1 with the protective ancestral “C” allele coding for the polar hydrophilic amino acid 
Threonine (ACG) and the risk “T” allele coding a non-polar hydrophobic Methionine 
(ATG) at amino acid position 509. This change is predicted to be “probably damaging” 
based on the program Polymorphism Phenotyping (PolyPhen). MMEL1, which is also 
known as Neprilysin 2 (NEP2), belongs to the M13 family of metalloendopeptidases. Unlike 
other members of this family that are ubiquitously expressed, MMEL1 expression is limited 
to the testis and CNS. In rodents, the largest isoform is predominantly expressed in testis, 
cleavage of this isoform producing a secreted soluble enzyme. The second isoform that is 23 
amino acids shorter is a membrane-associated protein highly expressed in the CNS.13 Little 
data exists though as to the exact function of the MMEL1 gene. As with other members of 
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the metalloendopeptidase family, MMEL1 appears to be involved in neuropeptide 
degradation,13 and a role in Alzheimer’s disease has also been suggested as it is involved in 
the degradation of beta-amyloid.14
The associated SNP lies within a region of extensive LD on chromosome 1 encompassing 
the MMEL1 gene and just extending to the tumour necrosis factor receptor superfamily 14 
gene (TNFRSF14). A SNP within TNFRSF14 (rs2234167) that lies on the boundary of this 
LD block was typed in the first replication stage but did not show any evidence for 
significance in the combined analysis of the original nsSNP screen and stage 1 replication 
data (p=0.2514). The LD between rs3748816 and rs2234167, as determined from the 4858 
individuals that were typed for both markers in stage 1 of the study, is low (D’=1, r2=0.083). 
Considerable work will be required to fine map this signal to ascertain if the signal is due to 
association with TNFRSF14 or MMEL1.
Two recent GWAS in rheumatoid arthritis (RA) also identified an association with the 
MMEL1 gene.12; 15 The SNPs tested in the RA screens (rs3890745 and rs10910099) were 
not analysed in the current study. Both SNPs though are in strong LD with rs3748816 
(r2=0.962 and 0.924 respectively based on HapMap data) with the major allele increasing 
susceptibility in both of the RA screens and in our study. Growing evidence suggests that 
there is an overlap in susceptibility factors between autoimmune diseases,16; 17 yet it 
remains to be determined if the association with MMEL1 in MS and RA is due to the same 
variant. Further work is required to fully establish the function of this gene and hence its 
potential role in MS disease pathogenesis.
A further three markers showed evidence for association in our final analysis with p-values 
< 0.001. While the evidence for association is not definitive, further analysis in larger 
samples is probably merited for all three markers. The strongest signal of these three 
markers was with rs2304497 in the ATP-citrate lyase (ACLY) gene. Rs2304497 lies in exon 
4 of ACLY and changes a glutamic acid (Glu) to aspartic acid (Asp) at amino acid position 
175, a change that is predicted to be “benign” (polyPhen). ACLY lies within the same LD 
block as the promoter for the 2′,3′-cyclic-nucleotide 3′-phosphodiesterase (CNP) gene on 
chromosome 17q, a gene which promotes microtubule assembly18 and in mice has been 
shown to be essential for axonal survival.19 The next strongest association was with 
rs4801853 in the c19orf48 which lies within a gene dense region on chromosome 19q13.33. 
In the initial analysis of our nsSNP screen and the stage 1 replication samples, six SNPs 
within this region were associated with MS at p <0.05. We only chose the most significantly 
associated SNP to study further. Amongst the genes in this region is a cluster of the 
kallikrein genes. Kallikreins are a family of serine proteases, of which KLK6 has been 
shown to be upregulated in MS plaques20 and both KLK1 and KLK6 have been implicated 
in degeneration and disease progression in MS.21 KLK1 and KLK3 have also been 
associated with susceptibility to Systemic Lupus Erythematosis (SLE).22 Finally, the 
association with the rs930557 marker in the Microcephalin (MCPH1) gene may be the result 
of uncorrected population stratification as this SNP is under strong positive selection in 
European and Asian populations.23
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At the time the WTCCC nsSNP screen was designed an attempt was made to include all 
known coding variants, however, the 12,374 SNPs included in the screen represent only a 
small fraction of such variants. The tendency for nsSNPs to have a lower allele frequency 
also means that even those that have been tested will probably not have been examined to a 
level where effects can be excluded. For example, in the combined analysis of our nsSNP 
screen and stage 1 replication data, at a 5% risk allele frequency we only have 53% power to 
identify a variant with an OR of 1.2 at a p-value < 0.05,24 making it likely that genuinely 
associated low frequency variants may have been missed. Furthermore, by screening only 
nsSNPs, other variations that may be involved in disease such as intronic or copy number 
variations will not have been captured. As with other genuine associations seen in complex 
genetic diseases, the associated variants we have identified in this and other studies have a 
relatively limited effect on an individual’s risk, but together the growing number of 
validated associations is helping to build a greater understanding of the mechanisms of 
disease pathogenesis.
In summary, we have found suggestive evidence for an association with rs3748816 in the 
MMEL1 gene. Independent replication and functional analysis will be necessary to fully 
confirm this locus as a genuine susceptibility gene in MS.
Materials and Methods
Samples
The first replication stage included subjects recruited through the University of Cambridge, 
UK; Brigham and Women’s Hospital in Boston, USA; and the University of California San 
Francisco, USA. Healthy unrelated controls were also included from both US sites and from 
the 1958 birth cohort in the UK. Controls were selected in order to optimise the matching of 
gender and age. The second replication stage included additional samples recruited through 
the University of Cambridge, UK; John Hunter Hospital Newcastle, Australia; and the 
University of Eastern Piedmont, Novara Italy. All samples were collected with informed 
written consent and appropriate local ethical approval. All patients satisfied recognised 
clinical criteria for the diagnosis of MS.25; 26 Subjects were chosen with all four main types 
of MS and varying disability. Full demographic features are provided in Table 1. The 
individuals included in the original WTCCC non-synonymous screen are described 
elsewhere.8
Markers
In the original WTCCC nsSNP screen a carefully developed set of over 15,000 nsSNPs were 
typed in five UK DNA sets: controls from the 1958 birth cohort (1958BC) and patient 
samples from individuals with MS, ankylosing spondylitis (AS), autoimmune thyroid 
disease (ATD) and breast cancer (BC). After the application of stringent quality control the 
primary MS specific component of the analysis (MS vs 1958BC) yielded reliable data from 
12,374 SNPs in up to 975 MS cases and 1466 controls. Two additional analyses were 
conducted using data from the other conditions considered in the project on the basis that for 
most variants these samples would represent reasonable “controls” in an analysis of 
susceptibility to MS. In the first of these additional analyses the MS data was compared with 
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that from all other samples considered (MS vs 1958BC+AS+AITD+BC) and in the second 
(an “immune” based analysis) the three autoimmune conditions were compared with the 
non-autoimmune samples (MS+AS+AITD vs 1958BC+BC). We used the following criteria 
to select markers for inclusion in our current follow-up effort:
1. P-value ranked within the top 1% of any of the three MS relevant analyses (n=303).
2. Having p<0.1 in both the main nsSNP analysis (MS vs 1958BC) and in the parallel 
screen performed by the International Multiple Sclerosis Genetics Consortium 
(IMSGC)4 (n=99). This obviously only applied to those variants that were included 
in both studies.
3. Any marker with a minor allele frequency of >5% and p<0.2 in the main nsSNP 
analysis (MS vs 1958BC) (n=1506).
After excluding the 18 SNPs we had previously investigated 9 these criteria identified a total 
of 1908 SNPs worthy of further follow up, of which 1853 were successfully genotyped. 
Following the application of stringent quality control measures (see below), 1664 of these 
gave reliable data.
Genotyping/Quality Control - stage 1
Genotyping was performed using the Illumina Infinium 60K BeadChip platform.27 The 
Illumina Infinium protocol involves amplification of genomic DNA, fragmentation of this 
DNA, hybridization of the DNA on the BeadChip, extension on the BeadChip, and imaging 
to read the chip. Samples were excluded if the genotyping efficiency was low (<95%). 
Similarly SNPs were excluded if the genotyping success rate was <95% or there was 
evidence of significant deviation from Hardy-Weinberg equilibrium (HWE) (p<0.001).
Genotyping/Quality Control - stage 2
The 13 SNPs considered in stage 2 of the replication were genotyped using TaqMan® 
Assays-On-Demand (Applied Biosystems). One of the SNPs however failed in the 
manufacturing process (rs12912505) so in total 12 SNPs were analysed. Genotyping was 
completed on a 7900 Sequence Detection System and plots generated and analysed using 
Sequence Detection System Software v2.1. All 12 SNPs fulfilled quality control 
requirements with a genotyping success rate >95% and Hardy-Weinberg equilibrium 
p>0.001. In this stage samples were excluded if the genotyping success was <50%. This 
resulted in the exclusion of a total of 48 samples, 14 from the Italian dataset (2 cases, 12 
controls) and 34 from the UK dataset (15 cases, 19 controls) which resulted in the final 
analysis of a total of 2406 cases and 1216 controls in the second stage replication effort.
Statistical analysis
Data quality checking and statistical analysis was completed using PLINK v 1.05. As the 
results of several populations were combined, we analysed the data using a Cochran-Mantel-
Haenzel test treating each population as a separate stratum and tested for heterogeneity 
between populations using the Breslow-Day statistic (see Table 2).
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Odds ratio for the rs3744816(T) allele in MMEL1
The area of the box is proportional to the number of cases included in the study. The error 
bars indicate the 95% confidence intervals. The population specific odds ratios are shown 
for reference.
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